TNF Pharmaceuticals Price to Free Cash Flow Ratio 2012-2024 | TNFA

TNF Pharmaceuticals price to free cash flow ratio from 2012 to 2024. Price to free cash flow ratio can be defined as

TNF Pharmaceuticals Price to Free Cash Flow Ratio 2012-2024 | TNFA

TNF Pharmaceuticals price to free cash flow ratio from 2012 to 2024. Price to free cash flow ratio can be defined as
Related Stocks
Company NameMarket
Cap
Zoetis (ZTS)$86.6B
Takeda Pharmaceutical (TAK)$46.8B
Merck (MKGAF)$24.9B
Summit Therapeutics (SMMT)$23.1B
Astellas Pharma (ALPMY)$21.7B
Sandoz Group AG (SDZNY)$17.9B
United Therapeutics (UTHR)$15.1B
Shionogi (SGIOY)$13.2B
Neurocrine Biosciences (NBIX)$12.3B
Catalent (CTLT)$10.8B
Orion OYJ (ORINY)$7.4B
Revolution Medicines (RVMD)$7.3B
Jazz Pharmaceuticals (JAZZ)$6.7B
Ionis Pharmaceuticals (IONS)$6.2B
Hikma Pharmaceuticals Plc (HKMPF)$5.7B
Madrigal Pharmaceuticals (MDGL)$5.3B
Crinetics Pharmaceuticals (CRNX)$4.3B
Corcept Therapeutics (CORT)$4B
Dyne Therapeutics (DYN)$3.4B
Arrowhead Pharmaceuticals (ARWR)$2.7B
AMNEAL PHARMACEUTICALS, INC (AMRX)$2.7B
PTC Therapeutics (PTCT)$2.6B
Catalyst Pharmaceuticals (CPRX)$2.4B
Soleno Therapeutics (SLNO)$2.1B
Centessa Pharmaceuticals (CNTA)$1.9B
Recursion Pharmaceuticals (RXRX)$1.8B
BioCryst Pharmaceuticals (BCRX)$1.6B
Harrow (HROW)$1.6B
Ardelyx (ARDX)$1.5B
NewAmsterdam Pharma (NAMS)$1.4B